Wegovy is a prescription medicine, so every route to it runs through a licensed clinician who evaluates whether it is appropriate for you. Two things vary, and it helps to keep them apart. Who writes the prescription: your own doctor, or a telehealth clinician licensed in your state. And where it is filled: a retail or mail pharmacy through your insurance, or the manufacturer’s direct-purchase pharmacy if you are paying yourself. A pharmacy fills a prescription someone has already written; it is not a third way of getting one.
If you have commercial insurance that covers Wegovy, that is almost always the place to start, and this page will not try to talk you out of it.
Who the label covers
Wegovy is approved for more than one thing, which surprises people who know it only as a weight-loss drug. The prescribing information lists the injection as indicated, alongside a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain that reduction in adults and patients aged 12 and older with obesity, and in adults with overweight who also have at least one weight-related condition; and for a specific liver condition in adults, under accelerated approval.
The label describes those populations as obesity and overweight rather than printing a number, and the same is true of Zepbound’s. The numbers you see quoted come from clinical practice rather than from the indications themselves. For assessing an adult for weight-management medication, the common starting framework is a body mass index of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnea (NIDDK).
Two things follow that are worth holding onto. Those figures are a screening framework for adults, not the definition of the categories: NIDDK puts overweight at a BMI between 25 and 30, so 27 is a treatment threshold rather than where overweight begins. And they do not transfer to adolescents or to the label’s other indications, which have their own criteria. A clinic that quotes you a BMI number as though it were the whole test is describing a screening rule, not a medical evaluation.
Some histories rule the medication out regardless of where you land on that scale. The label contraindicates Wegovy for anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2, and for anyone with a known hypersensitivity to semaglutide or the product’s other ingredients. It carries a boxed warning about thyroid C-cell tumours observed in rodents. That is the part of the conversation a real evaluation exists for.
Step one: the prescription
Any clinician licensed in your state and able to prescribe can write for Wegovy. That includes a primary care doctor, an endocrinologist, an obesity-medicine specialist, or a telehealth clinician. Semaglutide is not a controlled substance, so the stricter federal telehealth rules for controlled drugs do not apply, though ordinary state prescribing rules very much do. We cover how that works in practice at can you get a GLP-1 online without an in-person visit.
Bring your weight history, your other conditions and your full medication list. The evaluation is the point of the visit, not an obstacle in front of it.
Step two: find out what your plan actually does
Coverage for weight-management medication is inconsistent, and the honest answer for most people is that you cannot predict it. Ask your insurer one precise question: what would this exact prescription cost, after any required prior authorization, at an in-network pharmacy? Then ask whether that answer changes before and after your deductible. An estimate of benefits is not an approved claim.
Prior authorization is common here. It usually means your clinician has to document your diagnosis, your BMI and any related conditions, and sometimes previous attempts at weight management. It is paperwork, it takes days rather than minutes, and it is worth doing before you conclude the drug is unaffordable.
If you have commercial insurance that does cover Wegovy, the manufacturer’s savings offer can bring the cost down to as little as $25 a month for eligible patients, with the savings capped, so $25 is not what every covered patient pays. Government-insured patients are excluded from that commercial offer.
Medicare is its own case and has changed recently, so do not rely on older blanket statements that weight-loss drugs are never covered. The Medicare GLP-1 Bridge programme gives eligible Part D enrollees a $50 monthly copayment for specified products, Wegovy among them. It is a narrow route rather than general coverage: Medicare’s page sets out the eligibility, which turns on being 18 or over and meeting one of several BMI-plus-condition combinations, and it excludes people already receiving a GLP-1 through their Part D plan as well as people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease. Check it against your own situation rather than assuming either way.
Step three: if you are paying yourself
Novo Nordisk runs a direct-purchase programme with published self-pay prices, filled by CoAssist Pharmacy doing business as NovoCare Pharmacy. Checked on September 17, 2026, NovoCare lists the tablets at $149 a month for the 1.5 mg strength, $199 for 4 mg and $299 for 9 mg and 25 mg, where a month means one bottle of 30 tablets. The pens run a $199 introductory price for eligible new patients at the two starting strengths, good for two monthly fills through December 31, 2026, after which the listed strengths are $349 a month and the higher-dose 7.2 mg pen, Wegovy HD, is $399. A month of pens means one box of four weekly doses, which is not the same length as a calendar month.
Read those as different products at different prices rather than one product with a discount. A starting-dose advertisement tells you nothing about what your prescription will cost at the dose you end up on, which is the number worth asking for before you commit.
Where a compounded medication does and does not fit
Gentle Health does not prescribe or dispense Wegovy. We prescribe compounded semaglutide, which is prepared by a licensed pharmacy for an individual patient and is not an FDA-approved medication. It is not a generic Wegovy and not an equivalent of it. Those are different things with different evidence behind them, and the brand’s trial results are not evidence about a compounded preparation.
Whether a compounded preparation is appropriate is a medical question about you, decided by a prescriber. It is a different question from whether you can obtain or afford the approved product, and the two should not be run together: cost and availability are real considerations, but they are not by themselves a clinical reason to compound.
The regulatory ground also narrowed in 2025, once the FDA declared the semaglutide shortage resolved. For the state-licensed 503A pharmacies that prepare medication for an individual patient, the route that the shortage had opened closed, and what remains is narrower. It turns on a prescriber determining that a change made for a specific patient produces a significant difference for that patient, documented on the prescription, and the other requirements that apply to compounding still apply on top of that. Outsourcing facilities operate under a different section of the law with different conditions, so a claim about one does not describe the other. To be plain about the marketing question: presenting a compounded GLP-1 as a cheaper version of an approved brand was never accurate, during the shortage or since.
If, after all of that, a compounded preparation is what you and a physician decide on, our prices are published in full: oral semaglutide from $112 a month and injectable from $135, with every dose tier listed rather than a starting price and a surprise later. The complete tables are at how much does compounded semaglutide cost without insurance, and the reasons prices vary so wildly across this market are unpacked at Why Do GLP-1 Prices Vary So Much?.
Frequently asked questions
Can I get Wegovy without insurance? Yes. The manufacturer sells it directly at published self-pay prices, listed above and current as of September 17, 2026. You still need a prescription from a licensed clinician.
Is compounded semaglutide the same as Wegovy? No. Compounded medications are prepared for an individual patient and are not FDA-approved, so they are not generic or equivalent versions of the brand. The difference is explained further in the GLP-1 question library.
Does my state allow a GLP-1 prescription by telehealth? In most states a licensed clinician can evaluate you and prescribe without an in-person visit, though the rules differ and some states require a video visit. Each state we serve has its own page on our states page.
Dr. James Simmons, MD